Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(3.87)
# 1,946
Out of 5,136 analysts
86
Total ratings
39%
Success rate
10.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVAX Novavax | Reiterated: Buy | $18 | $8.06 | +123.33% | 5 | Nov 5, 2026 | |
| VERA Vera Therapeutics | Reiterated: Buy | $100 | $26.97 | +270.78% | 14 | Nov 5, 2026 | |
| AXSM Axsome Therapeutics | Reiterated: Buy | $272 | $137.01 | +98.53% | 6 | Nov 2, 2026 | |
| ABOS Acumen Pharmaceuticals | Downgraded: Sell | n/a | $0.216 | - | 4 | Oct 30, 2026 | |
| RZLT Rezolute | Upgraded: Buy | n/a | $3.58 | - | 7 | Oct 5, 2026 | |
| NVCT Nuvectis Pharma | Initiated Coverage: Buy | n/a | $19.11 | - | 1 | Aug 24, 2026 | |
| PMN ProMIS Neurosciences | Initiated Coverage: Buy | $40 | $3.31 | +1,100.91% | 1 | Jun 29, 2026 | |
| ALEC Alector | Upgraded: Buy | n/a | $2.57 | - | 3 | Apr 15, 2026 | |
| ALKS Alkermes | Reiterated: Buy | $43 | $46.53 | -7.59% | 1 | Mar 11, 2026 | |
| CRVO CervoMed | Initiated Coverage: Buy | n/a | $1.67 | - | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $89.55 | n/a | 2 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.97 | n/a | 5 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $11.77 | n/a | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $22.61 | n/a | 1 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $8.31 | n/a | 7 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.57 | n/a | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $0.6932 | n/a | 8 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $1.63 | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $7.70 | n/a | 4 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $17.61 | n/a | 3 | Jun 23, 2023 |
Novavax
Nov 5, 2026
Reiterated: Buy
Price Target: $18
Current: $8.06
Upside: +123.33%
Vera Therapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: $100
Current: $26.97
Upside: +270.78%
Axsome Therapeutics
Nov 2, 2026
Reiterated: Buy
Price Target: $272
Current: $137.01
Upside: +98.53%
Acumen Pharmaceuticals
Oct 30, 2026
Downgraded: Sell
Price Target: n/a
Current: $0.216
Upside: -
Rezolute
Oct 5, 2026
Upgraded: Buy
Price Target: n/a
Current: $3.58
Upside: -
Nuvectis Pharma
Aug 24, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $19.11
Upside: -
ProMIS Neurosciences
Jun 29, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $3.31
Upside: +1,100.91%
Alector
Apr 15, 2026
Upgraded: Buy
Price Target: n/a
Current: $2.57
Upside: -
Alkermes
Mar 11, 2026
Reiterated: Buy
Price Target: $43
Current: $46.53
Upside: -7.59%
CervoMed
Dec 18, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $1.67
Upside: -
Aug 22, 2025
Reiterated: Buy
Price Target: n/a
Current: $89.55
Upside: n/a
Jul 10, 2025
Reiterated: Buy
Price Target: n/a
Current: $1.97
Upside: n/a
Jul 7, 2025
Downgraded: Hold
Price Target: n/a
Current: $11.77
Upside: n/a
Jul 2, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $22.61
Upside: n/a
Jul 1, 2025
Reiterated: Buy
Price Target: n/a
Current: $8.31
Upside: n/a
May 13, 2025
Reiterated: Buy
Price Target: n/a
Current: $3.57
Upside: n/a
Mar 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $0.6932
Upside: n/a
Jan 10, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $1.63
Upside: n/a
Aug 8, 2023
Reiterated: Buy
Price Target: $34
Current: $7.70
Upside: n/a
Jun 23, 2023
Rated: Hold
Price Target: n/a
Current: $17.61
Upside: n/a